Heart failure (HF) is a progressive disease, affecting more than 60 million people worldwide [1]. Despite advances in treatment options, HF is associated with a high risk of mortality and morbidity. The clinical trajectory of HF is characterized by phases of symptomatic stability, often interrupted by episodes of worsening, despite ongoing medical therapy. When HF progresses towards clinical deterioration and escalating symptoms and signs that necessitate intravenous diuretic treatment in an outpatient, emergency department, or hospital setting, it is referred to as Worsening Heart Failure (WHF) [2,3].
